Myeloproliferative neoplasms research hub
5 indexed studies · 4 currently recruiting
- recruitingPhase I
A study to test the safety of INCB160058 in participants with blood cancers
This study is testing a new medicine, INCB160058, for blood cancers called myeloproliferative neoplasms (MPNs). These cancers make too many blood cells. The study aims to find the right dose, check for side effects, and see if it helps patients, sometimes alongside another medicine called ruxolitinib.
United Kingdom · England · Canada - recruitingPHASE1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
This study looks at a new drug, INCA033989, alone or with ruxolitinib, for blood cancers called myeloproliferative neoplasms. Researchers want to find a safe and effective dose, checking for side effects and how well patients can tolerate the treatment.
Australia · Canada · Denmark - recruitingPHASE1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
This study is testing a new medicine, INCA036978, for people with certain blood conditions called myeloproliferative neoplasms (MPNs). We want to see if it's safe, what dose works best, and if it can be combined with other treatments.
United States · Australia · Belgium - recruitingPHASE1
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
This study is looking at a new medicine called INCB160058 for people with certain blood conditions called Myeloproliferative Neoplasms (MPN). Researchers want to see if it's safe, how well people tolerate it, and how it moves through the body.
United States · Canada · France - recruitingPHASE1
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
This study is looking into a new medicine, INCA035784, for people with blood cancers called myeloproliferative neoplasms (MPNs). The main goal is to check how safe it is and if people can tolerate it well, meaning how their bodies react to the treatment.
United States · Australia · Belgium